FDA Approves New Regimen for Metastatic Breast Cancer Maintenance

The U.S. FDA has granted approval for a new treatment regimen combining palbociclib with trastuzumab, potentially alongside pertuzumab and endocrine therapy. This approval is for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer who have not progressed after initial therapy.